Point72 Hong Kong Ltd Boosts Holdings in Qiagen (NYSE:QGEN)

Point72 Hong Kong Ltd increased its holdings in Qiagen (NYSE:QGEN) by 172.2% in the third quarter, Holdings Channel.com reports. The firm owned 64,161 shares of the company’s stock after acquiring an additional 40,589 shares during the period. Point72 Hong Kong Ltd’s holdings in Qiagen were worth $2,924,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. PDT Partners LLC grew its position in Qiagen by 77.1% during the 3rd quarter. PDT Partners LLC now owns 104,424 shares of the company’s stock worth $4,759,000 after acquiring an additional 45,449 shares during the last quarter. Verition Fund Management LLC purchased a new stake in shares of Qiagen during the third quarter valued at approximately $1,169,000. Capstone Investment Advisors LLC bought a new position in shares of Qiagen in the third quarter worth approximately $395,000. Public Sector Pension Investment Board increased its stake in shares of Qiagen by 23.7% in the third quarter. Public Sector Pension Investment Board now owns 115,032 shares of the company’s stock worth $5,232,000 after buying an additional 22,039 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Qiagen by 44.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 218,127 shares of the company’s stock valued at $9,852,000 after buying an additional 67,143 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on QGEN. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday, October 17th. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Qiagen currently has a consensus rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Price Performance

Shares of NYSE QGEN opened at $43.43 on Monday. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The stock has a market capitalization of $9.91 billion, a P/E ratio of 111.36, a P/E/G ratio of 3.37 and a beta of 0.41. The company’s 50-day moving average is $43.22 and its 200 day moving average is $43.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.